DANVERS, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Medwave, Inc. announced today that a study titled, “Self-reported Sensitivity to Continuous Noninvasive Blood Pressure Monitoring Via the Radial Artery,” performed at Virginia Polytechnic Institute and State University in Blacksburg, VA, was recently published by the Journal of Psychosomatic Research. The purpose of the study was to examine the utility of the Vasotrac non-invasive blood pressure monitor primarily in regard to its intrusiveness after prolonged continual readings. Non-invasive blood pressure measurement has extensive use in psychosomatic and behavioral research, but many methods for blood pressure assessment in such studies produce numerous research limitations, such as discomfort, sampling limits, and measurement validity concerns. The study concluded that the Vasotrac is non-intrusive during extended wear, as well as capable of producing a sampling rate that far exceeds that of other methods for non-invasive blood pressure assessment.
Corresponding Author, Bruce H. Friedman, Ph.D., Associate Professor, Department of Psychology of Virginia Tech, Blacksburg, Virginia, stated, “The Vasotrac may hold particular utility for psychosomatic and social science research as it seems to avoid problems associated with prolonged, repeated inflation and deflation of brachial artery and finger cuffs. As such, the Vasotrac offers reliable blood pressure assessment that does not pose a significant source of discomfort, potential tissue damage, or distraction during sensitive experimental manipulations.”
Rich Niemczyk, Product Marketing Manager for Medwave, Inc., notes, “Although the study concludes the importance of the Vasotrac technology in a research environment, we are excited by the fact that comfort for patients applies in any healthcare environment. We have received reports from numerous individuals who have experienced discomfort and even sleep disruption due to the occlusive nature of a blood pressure cuff. This study further validates the fact that not only will our technology be more comfortable, but if needed, the Vasotrac can provide more readings in less time.”
Medwave, Inc. develops, manufactures, and distributes non-invasive blood pressure monitoring products. Its Vasotrax(R) Hand Held Monitor, the Vasotrac(R) APM205A NIBP Monitor, the Vasotrac APM205A Model DS, and the MJ23 OEM Module are new approaches to non-invasive blood pressure monitoring. Medwave has received the necessary regulatory clearances to market its technology in Europe, Asia, and the United States. Medwave is ISO13485/ISO9001/MDD93/42/EEC certified, and all of its products are CE marked. Medwave previously received the Seal of Acceptance from the Alliance of Children’s Hospitals, as well as the Frost and Sullivan Market Engineering Award for Technology Innovation. Medwave’s technology is installed in over 500 hospitals and clinics worldwide. The company trades on the NASDAQ small cap market under the symbol MDWV.
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered “forward-looking statements” and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in the Company’s filings with the SEC, have affected and, in the future, could affect the Company’s actual results: resistance to the acceptance of new medical products, the market acceptance of the Vasotrac(R) system and other products of the Company, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of the Company’s products, the Company’s success in creating effective distribution channels for its products, the Company’s ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), and Vasotrax(R) are trademarks of Medwave, Inc.
Medwave, Inc.
CONTACT: Medwave, Inc. Investor Relations, +1-978-762-8999
Web site: http://www.medwave.com/